First-of-its-Kind cell therapy trial launches for MS
NCT ID NCT07364487
Summary
This is an early, exploratory study to test the safety and initial effectiveness of a new therapy called GC012F for people with multiple sclerosis (MS). The therapy involves collecting a patient's own immune cells, modifying them in a lab to potentially target MS, and then infusing them back. The study will enroll 15 participants to closely monitor for side effects and early signs that the treatment might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.